RU2654702C2 - Способы и композиции для лечения боли, включающие трансдермальные композиции на основе дексмедетомидина - Google Patents

Способы и композиции для лечения боли, включающие трансдермальные композиции на основе дексмедетомидина Download PDF

Info

Publication number
RU2654702C2
RU2654702C2 RU2016109631A RU2016109631A RU2654702C2 RU 2654702 C2 RU2654702 C2 RU 2654702C2 RU 2016109631 A RU2016109631 A RU 2016109631A RU 2016109631 A RU2016109631 A RU 2016109631A RU 2654702 C2 RU2654702 C2 RU 2654702C2
Authority
RU
Russia
Prior art keywords
dexmedetomidine
subject
transdermal delivery
pain
hours
Prior art date
Application number
RU2016109631A
Other languages
English (en)
Russian (ru)
Other versions
RU2016109631A (ru
Inventor
Адчара ПОНГПЕЕРАПАТ
Амит ЯИН
Брет БЕРНЕР
Яни Вен
Ютаро Шудо
Original Assignee
ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. filed Critical ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.
Publication of RU2016109631A publication Critical patent/RU2016109631A/ru
Application granted granted Critical
Publication of RU2654702C2 publication Critical patent/RU2654702C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2016109631A 2013-10-07 2014-10-03 Способы и композиции для лечения боли, включающие трансдермальные композиции на основе дексмедетомидина RU2654702C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887870P 2013-10-07 2013-10-07
US61/887,870 2013-10-07
PCT/US2014/059057 WO2015054062A2 (en) 2013-10-07 2014-10-03 Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions

Publications (2)

Publication Number Publication Date
RU2016109631A RU2016109631A (ru) 2017-11-15
RU2654702C2 true RU2654702C2 (ru) 2018-05-22

Family

ID=52777129

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016109631A RU2654702C2 (ru) 2013-10-07 2014-10-03 Способы и композиции для лечения боли, включающие трансдермальные композиции на основе дексмедетомидина

Country Status (10)

Country Link
US (2) US20150098982A1 (https=)
EP (1) EP3054931B1 (https=)
JP (2) JP6188934B2 (https=)
KR (2) KR20180095733A (https=)
CN (2) CN110604728A (https=)
CA (1) CA2924188C (https=)
ES (1) ES2855103T3 (https=)
RU (1) RU2654702C2 (https=)
TW (1) TWI629061B (https=)
WO (1) WO2015054062A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
BR112016006848A2 (pt) 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
EP3054931B1 (en) * 2013-10-07 2020-12-23 Teikoku Pharma USA, Inc. Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions
TWI764951B (zh) * 2016-10-31 2022-05-21 美商帝國製藥美國股份有限公司 用於處理疼痛之右美托咪啶經皮遞送裝置
KR102793584B1 (ko) 2016-12-31 2025-04-09 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
PL3813802T3 (pl) 2018-06-27 2025-04-22 Bioxcel Therapeutics, Inc. Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
WO2020222192A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
EP3962478A1 (en) 2019-05-01 2022-03-09 Clexio Biosciences Ltd. Methods of treating pruritus
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
WO2024037545A1 (zh) * 2022-08-17 2024-02-22 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0413487A1 (en) * 1989-08-18 1991-02-20 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
RU2392278C2 (ru) * 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
EA014504B1 (ru) * 2006-04-26 2010-12-30 Дбв Текноложи Пластырь и его использование
WO2011085162A2 (en) * 2010-01-08 2011-07-14 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
CA2222133C (en) * 1995-06-07 2002-12-24 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
NZ510771A (en) * 1998-10-02 2003-08-29 3M Innovative Properties Co Mucosal originated drug delivery systems
KR100511492B1 (ko) * 2002-10-11 2005-08-31 주식회사 태평양 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제
JP4694967B2 (ja) * 2003-07-31 2011-06-08 久光製薬株式会社 貼付剤
MXPA06002716A (es) * 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US20070134310A1 (en) * 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
EP2308480B1 (en) * 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
US20090258063A1 (en) * 2006-09-11 2009-10-15 Sekisui Chemical Co., Ltd. Transdermal patch
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
JP5547065B2 (ja) * 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
EP2330903A4 (en) * 2008-07-28 2011-10-12 Endogenx Inc METHOD FOR TREATING PAIN USING AN ALPHA-2 ADRENEER AGONIST AND AN ENDOTHELINE ANTAGONIST
US9308203B2 (en) * 2008-10-01 2016-04-12 Taiwan Biotech Co., Ltd. Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis
US8563031B2 (en) * 2010-05-27 2013-10-22 Absize, Inc. Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
CN103200944B (zh) * 2010-11-17 2016-05-04 赫克萨尔股份公司 包含丁丙诺啡的经皮治疗系统
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
EP3054931B1 (en) * 2013-10-07 2020-12-23 Teikoku Pharma USA, Inc. Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0413487A1 (en) * 1989-08-18 1991-02-20 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
RU2392278C2 (ru) * 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
EA014504B1 (ru) * 2006-04-26 2010-12-30 Дбв Текноложи Пластырь и его использование
WO2011085162A2 (en) * 2010-01-08 2011-07-14 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
WU F. et al. Inhibition of GAP-43 by propentofylline in a rat model of neuropathic pain// Int J Clin Exp Pathol. 2013 Jul 15; 6(8):1516-22. *
КАРЛОВ В.А. Терапия нервных болезней// М., 1996, с.607-612. *
КАРЛОВ В.А. Терапия нервных болезней// М., 1996, с.607-612. WU F. et al. Inhibition of GAP-43 by propentofylline in a rat model of neuropathic pain// Int J Clin Exp Pathol. 2013 Jul 15; 6(8):1516-22. *

Also Published As

Publication number Publication date
CA2924188C (en) 2018-12-18
EP3054931A2 (en) 2016-08-17
US20240245652A1 (en) 2024-07-25
JP2018008984A (ja) 2018-01-18
EP3054931A4 (en) 2017-04-05
ES2855103T3 (es) 2021-09-23
TW201524506A (zh) 2015-07-01
JP6188934B2 (ja) 2017-08-30
RU2016109631A (ru) 2017-11-15
KR20180095733A (ko) 2018-08-27
BR112016007327A2 (pt) 2017-08-01
CN105764495A (zh) 2016-07-13
EP3054931B1 (en) 2020-12-23
TWI629061B (zh) 2018-07-11
JP6522062B2 (ja) 2019-05-29
KR101891186B1 (ko) 2018-08-24
JP2016532645A (ja) 2016-10-20
KR20160062159A (ko) 2016-06-01
CN110604728A (zh) 2019-12-24
WO2015054062A2 (en) 2015-04-16
CA2924188A1 (en) 2015-04-16
US20150098982A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
RU2654702C2 (ru) Способы и композиции для лечения боли, включающие трансдермальные композиции на основе дексмедетомидина
RU2646512C2 (ru) Устройства для трансдермальной доставки дексмедетомидина и способы их применения
RU2658463C2 (ru) Способы и композиции для лечения синдрома дефицита внимания и гиперактивности, тревожности и бессонницы с применением трансдермальных композиций на основе дексмедетомидина
RU2648449C2 (ru) Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
JP6370802B2 (ja) 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
JP6208859B6 (ja) デクスメデトミジン経皮送達デバイス及びその使用法
HK40018815A (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
BR112016007327B1 (pt) Uso de dispositivo de distribuição transdérmica para controlar dor